
Induced Demand in Cancer Diagnosis
Author(s) -
Mohammad Esmaeil Akbari,
Abbas Assari Arani,
Mohammad Esmaeil Akbari,
Bahram Sahabi,
Alireza Olyaeemanesh
Publication year - 2020
Publication title -
international journal of cancer management
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.251
H-Index - 19
eISSN - 2538-4422
pISSN - 2538-497X
DOI - 10.5812/ijcm.106281
Subject(s) - overdiagnosis , scopus , medicine , cancer , harm , context (archaeology) , intensive care medicine , medline , pathology , psychology , political science , social psychology , paleontology , law , biology
Context: Supplier-induced demand (SID) is an essential concept in health economics related to the diagnosis of different types of cancer and related expenditures. The current review considered studies on induced demand in cancer diagnosis. Evidence Acquisition: This systematic review investigated the induced diagnosis of cancer in four well-known databases (Scopus, Science Direct, Web of Science, and PubMed) from January 1980 to July 2019 using the keywords “induced demand,” “cancer,” and “diagnosis”. References of the studies found through the original search were also considered for analysis. Results: No studies focused on SID in cancer diagnosis could be found, thus indicating a significant deficiency in the discussion of SID in cancer diagnosis studies. Therefore, the terms most relevant to the concept of SID in cancer diagnosis were examined. Finally, 24 factors were categorized into three groups: economic, socio-cultural, and structural. The majority of evidence for the probability of SID in cancer diagnosis is related to overdiagnosis or early diagnosis caused by unnecessary screening (57.14% of reviewed articles) and the neglect of clinical practice guidelines (42.8% of reviewed articles), mainly by diagnostic imaging. Conclusions: Research focused explicitly on SID in cancer diagnosis is needed. Moreover, economic, social, and structural reforms related to the factors that connect overuse, overdiagnosis, and unnecessary services to cancer diagnosis are required to control costs and harm and provide the best benefits to patients.